ValuEngine upgraded shares of NextCure (NASDAQ:NXTC) from a hold rating to a buy rating in a research report released on Monday morning, ValuEngine reports.
Several other equities research analysts have also recently weighed in on NXTC. Zacks Investment Research cut NextCure from a buy rating to a hold rating in a research report on Wednesday, July 8th. Piper Sandler decreased their price target on NextCure from $87.00 to $32.00 in a research report on Monday. Roth Capital cut NextCure from a buy rating to a neutral rating and set a $15.00 price target on the stock. in a research report on Monday. Benchmark cut NextCure from a buy rating to a hold rating in a research report on Monday, June 1st. Finally, BidaskClub cut NextCure from a sell rating to a strong sell rating in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of $30.64.
Shares of NASDAQ:NXTC opened at $9.08 on Monday. The company’s 50-day moving average is $23.77 and its 200 day moving average is $37.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 40.07 and a current ratio of 40.07. The company has a market capitalization of $249.86 million, a P/E ratio of -9.17 and a beta of -0.05. NextCure has a fifty-two week low of $8.00 and a fifty-two week high of $109.00.
NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.77. The business had revenue of $22.38 million for the quarter, compared to the consensus estimate of $1.30 million. NextCure had a negative net margin of 65.22% and a negative return on equity of 7.12%. As a group, research analysts predict that NextCure will post -1.16 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA boosted its stake in NextCure by 277.8% in the first quarter. BNP Paribas Arbitrage SA now owns 6,173 shares of the company’s stock worth $229,000 after buying an additional 4,539 shares in the last quarter. UBS Group AG boosted its stake in NextCure by 1,564.2% in the first quarter. UBS Group AG now owns 9,153 shares of the company’s stock worth $339,000 after buying an additional 8,603 shares in the last quarter. Bank of America Corp DE boosted its stake in NextCure by 531.4% in the fourth quarter. Bank of America Corp DE now owns 66,545 shares of the company’s stock worth $3,748,000 after buying an additional 56,005 shares in the last quarter. State Street Corp boosted its stake in NextCure by 7.7% in the first quarter. State Street Corp now owns 448,844 shares of the company’s stock worth $16,639,000 after buying an additional 32,282 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in NextCure by 12.1% in the first quarter. Geode Capital Management LLC now owns 183,252 shares of the company’s stock worth $6,793,000 after buying an additional 19,779 shares in the last quarter. 73.44% of the stock is owned by institutional investors and hedge funds.
NextCure Company Profile
There is no company description available for NextCure Inc
Read More: Hedge Funds – Risk or Reward?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.